Intuitive Surgical’s (ISRG) story is improving. A new product was developed as an upgrade to the existing daVinci Surgical System. Furthermore, the company enjoys a virtual monopoly in robotic surgery without
direct competition.
The company’s razor/razor blade
business model ensures recurring revenues even
during difficult times. In the second quarter, earnings
of $1.62 per share were higher than the Zacks
Consensus Estimate of $1.27.
Growth in revenues
was witnessed across all the segments. We believe
the company will continue leveraging its monopoly
position in the industry. We rate this stock
Outperform with a target price of $260 per share.Zacks Investment Research
